DalCor Pharmaceuticals US, LLC — Form D/A
DalCor Pharmaceuticals US, LLC of SAN MATEO, CA, a company, filed a Form D amendment with the SEC on 2017-05-12. The offering totals $110.0M, of which $55.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2017-05-12
- Form: D/A
- Accession: 0001673368-17-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $110.0M
- Amount sold: $55.0M
- Remaining: $55.0M
- Investors: 47
- Date of first sale: 2016-04-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-263148
Issuer
- Name: DalCor Pharmaceuticals US, LLC
- CIK: 0001673368
- Entity type: Limited Liability Company
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 400 S. EL CAMINO REAL, SUITE 1200 400 S. El Camino Real, Suite #1200, SAN MATEO, CA, 94402
- Phone: 650-401-2000
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Thomas Michael Birch | Director | Montreal, A8 |
| D. Michael Dixon | Director | Montreal, A8 |
| Ga?tan Michael Gravel | Director | Montreal, A8 |
| Robert McNeil | Director | San Diego, CA |
| Laurence Michael Rulleau | Director | Montreal, A8 |
| Mark Michael Smith | Director | Montreal, A8 |
| Rody Michael Yared | Director | Montreal, A8 |
| D. Michael Dixon | Executive Officer | Montreal, A8 |
| Robert McNeil | Executive Officer | San Diego, CA |
| Louise Michael Proulx | Executive Officer | Montreal, A8 |
| Robert McNeil | Promoter | San Diego, CA |
| Paul Fonteyne | Director | New Haven, CT |
| Donald Black | Director | Sarasota, FL |
| D. Michael Dixon | Director | Sarasota, FL |
| Didier Michael Leconte | Director | Montreal, A8 |
Other filings by this issuer (3)
More